First Week of September 18th Options Trading For Travere Therapeutics (TVTX)

Travere Therapeutics (TVTX) options present income-oriented trade ideas: a $27.50 put is bid $5.40 (implying a net cost basis of $22.10 if assigned) with a 67% probability of expiring worthless and a 19.64% return on cash commitment (29.26% annualized). On the call side, a $30.00 September 18 covered call is bid $6.20, producing a 26.75% total return if called away and a 21.71% yield boost (32.35% annualized) with a 37% chance of expiring worthless. Implied volatilities are elevated (puts 92%, calls 91%) versus trailing 12‑month volatility of 68%, indicating substantial option premium and dispersion for income/covered-call or cash-secured-put strategies.

Analysis

Market structure: The high implied vol (calls 91%/puts 92% vs TTM 68%) and rich option premiums benefit option sellers, market-makers, and yield-focused funds willing to take assignment risk; NDAQ benefits from elevated derivatives flow. Put-selling interest at $27.50 (67% chance to expire worthless) signals latent buy-side willingness to own TVTX at a ~22% lower effective cost basis ($22.10) than today, while covered-call activity caps upside for holders and concentrates returns in near-term income rather than long-term capital gains.

Risk assessment: Tail risks are classic biotech binaries—FDA/trial negatives or clinical holds—that could erase >30–50% of market cap within days; conversely, a positive readout could gap shares well above the $30 covered-call cap. Near-term (days–weeks) repricing will be driven by IV mean reversion toward ~68% and any scheduled catalysts before Sept 18 expiry; medium/long-term fundamentals (revenue, approvals) determine sustainable valuation beyond option cycles.

Trade implications: For income-oriented exposure, selling the Sep18 $27.50 put (collect $5.40 → net basis $22.10) is attractive if you can buy/hold shares at that basis; size positions small (1–3% portfolio) and use short-put spreads (sell $27.50 / buy $22.50) to cap tail risk. If long TVTX, sell the Sep18 $30 call to lock ~26.75% return to expiry but hedge with a $27.50 protective put if downside >15% is unacceptable; consider long-calendar or long-dated calls only if expecting a positive binary >3 months out.

Contrarian angles: Consensus treats IV as permanent; history shows biotech IV can collapse 30–60% absent binary events—creating mispriced premium for sellers. The market may be underpricing the probability of assignment-driven accumulation at low cost base; unintended consequence for large sellers is being forced to hold illiquid, high-beta stock through a binary event. If a positive catalyst is within 60–120 days, covered calls and naked puts are likely to underperform a long equity stance by 25–50% on upside.

Key Decisions for Investors

• Establish a capped 1–2% portfolio position by selling the Sep 18 TVTX $27.50 put (collect ~$5.40) only if you have cash to buy at $22.10; close or roll if IV falls below 70% or TVTX price moves >+10%.
• If already long TVTX, sell the Sep 18 $30 covered call to realize ~26.75% to expiry (size 1–3% of portfolio); buy a Sep $27.50 put as protection if maximum drawdown exposure >15%.
• For defined-risk income, implement a short-put vertical (sell Sep $27.50, buy Sep $22.50) sized to 1% portfolio; accept capped max loss = strike width minus net credit and target >10% return on risk to expiry.
• Reduce crowding into small-cap biotech beta by 1–2% over the next 30 days—rotate into larger-cap or diversified healthcare (e.g., XLV) if IV across your biotech book >80% and you lack capacity to absorb binary assignment events.